SCN1A rs6732655A/T polymorphism: Diagnostic and therapeutic insights for drug-resistant epilepsy

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

HTML

Figures (1-2)

Tables (1-5)

Sum=0

Sep 20, 2024 (publication date) through Aug 29, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Experimental Medicine

ISSN

2220-315x

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Exp Med. Sep 20, 2024; 14(3): 94999
Published online Sep 20, 2024. doi: 10.5493/wjem.v14.i3.94999

Table 3 Risk of drug resistance associated with rs6732655 genotypes

CI: Confidence interval; OR: Odds ratio; Ref: Reference polymorphism in OR analysis; SNP: Single nucleotide polymorphism.

Citation: Viswas A, Dabla PK, Shrivastav D, Gupta S, Yadav M, Yadav S, Koner BC. SCN1A rs6732655A/T polymorphism: Diagnostic and therapeutic insights for drug-resistant epilepsy. World J Exp Med 2024; 14(3): 94999
URL: https://www.wjgnet.com/2220-315x/full/v14/i3/94999.htm
DOI: https://dx.doi.org/10.5493/wjem.v14.i3.94999